Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Replimune Inc.
National Cancer Institute (NCI)
Incyte Corporation
Compugen Ltd
Bristol-Myers Squibb
Osaka University
Celgene
Bristol-Myers Squibb